Track Sun Pharmaceutical Industries live share price, 52 week range, interactive chart, fundamentals, business segments, financial highlights, shareholding, ratios, peers, corporate actions and investor FAQs.
Switch between 1 Day, 5 Day, 1 Month and 1 Year chart views.
Sun Pharmaceutical Industries Limited is a global pharmaceutical company headquartered in India. It develops, manufactures and markets branded generics, generic medicines, specialty medicines, active pharmaceutical ingredients and selected consumer healthcare products across India, the United States and other international markets.
The company’s investor story combines a large India formulations franchise with international generics and a growing global specialty portfolio. Its specialty focus includes complex and differentiated therapies, while the broader business also depends on product launches, manufacturing quality, distribution reach and regulatory approvals.
Key monitorables include India market growth, US sales, global specialty sales, operating margin, R&D spending, regulatory compliance, product approvals, patent and litigation outcomes, acquisitions, cash generation and capital allocation.
Investors commonly track India formulations, US formulations, emerging markets, rest-of-world markets, global specialty products and APIs. Reported categories can change, so use the latest annual report and quarterly presentation for the current segment definition.
Sun Pharma generates revenue by researching, developing, manufacturing, licensing and selling medicines. It operates through branded formulations in India and emerging markets, generic and specialty products in the United States, products in other international markets, and APIs used internally or sold to third parties.
Specialty medicines can offer differentiated growth but typically require higher clinical, regulatory and commercial investment. Generic medicines can provide scale but may face price erosion and competition. India branded formulations benefit from physician relationships, therapy presence and distribution, while international performance also depends on currency, regulation and product approvals.
Retail investors should distinguish sustainable operating growth from one-off gains, exceptional charges, litigation settlements and acquisition-related accounting.
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Revenue from Operations | ₹43,885.7 Cr | ₹48,496.9 Cr | ₹52,578.4 Cr |
| Net Profit | ₹8,473.6 Cr | ₹9,576.4 Cr | ₹10,929.0 Cr |
| Net Profit Margin | 19.3% | 19.7% | 20.8% |
| EPS | Verify filing | Verify filing | Verify filing |
| R&D and Specialty Investment | Material | Material | Material |
| Particulars | Mar 2024 | Mar 2025 | Investor Reading |
|---|---|---|---|
| Total Assets | ₹41,064.8 Cr | ₹43,273.5 Cr | Asset base increased year on year |
| Cash and Cash Equivalents | ₹326.5 Cr | ₹492.0 Cr | Excludes other bank balances and investments |
| Investments | ₹12,430.0 Cr | ₹12,410.1 Cr | Large treasury and strategic investment balance |
| Inventories | ₹3,423.6 Cr | ₹3,787.5 Cr | Relevant for manufacturing and product supply |
| Trade Receivables | ₹8,834.2 Cr | ₹11,701.4 Cr | Monitor collection cycle and geographic mix |
| Area | What to review | Why it matters | Verification |
|---|---|---|---|
| Operating Cash Flow | Cash generated from the core pharmaceutical business | Supports R&D, dividends and acquisitions | Check the latest consolidated cash-flow statement |
| Capital Expenditure | Manufacturing, quality, capacity and technology investment | Can support growth but reduces near-term free cash flow | Check annual report notes |
| Acquisitions and Licensing | Upfront, milestone and acquisition payments | May expand specialty portfolio and add integration risk | Check exchange filings |
| Free Cash Flow | Operating cash flow less capital expenditure | Useful measure of financial flexibility | Recalculate from latest filing |
| Metric | How to read it | Key monitorable | Verification |
|---|---|---|---|
| Revenue Growth | Compare annual and quarterly growth | Watch India, US and specialty mix | Verify latest results |
| Operating Margin | Tracks profitability before finance cost and tax | Product mix and R&D can move margins | Verify latest results |
| Return on Equity | Measures profit relative to shareholder equity | Compare across multi-year periods | Verify latest annual report |
| Debt Position | Review gross debt, cash and investments | Important for acquisitions and capital allocation | Verify latest balance sheet |
| Valuation Ratios | P/E, price-to-book and EV-based ratios | Market prices change continuously | Use current market data |
| Company | NSE Symbol | Business Profile | Key Comparison |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | SUNPHARMA | India, US, specialty and global generics | Scale, specialty mix, margins and valuation |
| Dr. Reddy’s Laboratories Ltd | DRREDDY | Global generics and pharmaceutical services | US exposure, pipeline and margins |
| Cipla Ltd | CIPLA | India, respiratory and international formulations | India franchise, US products and margin |
| Divi’s Laboratories Ltd | DIVISLAB | APIs and custom synthesis | Manufacturing model, customer concentration and margin |
| Lupin Ltd | LUPIN | Generics, branded formulations and specialty products | US recovery, India growth and compliance |
| Year | Dividend Detail | Note |
|---|---|---|
| Latest declared dividend | Verify the latest amount and record date | Use company and exchange announcements |
| Dividend history | Sun Pharma has a history of dividend payments | Past dividends do not guarantee future dividends |
| Tax and entitlement | Depends on applicable law and record-date ownership | Consult official communication or a tax professional |
| Action | Detail | Note |
|---|---|---|
| Bonus Issue | Verify official historical records | Check BSE, NSE and company filings |
| Stock Split | Verify official historical records | Adjusted chart prices may differ from raw historical prices |
| Face Value | Verify latest exchange master data | Corporate actions can change per-share comparability |
Verify the latest financial results, shareholding pattern, dividend, bonus, split and record-date information from Sun Pharma’s investor-relations website and official NSE/BSE filings before relying on it.
These FAQs explain the company’s products, business model, risks, dividends, peer context and the indicators retail investors commonly monitor.
Sun Pharmaceutical Industries is an Indian pharmaceutical company with businesses across branded generics, generic medicines, specialty medicines, active pharmaceutical ingredients and consumer healthcare. Its products are sold in India, the United States and several other international markets.
The company is commonly analysed through India formulation sales, United States formulation sales, emerging-market sales, rest-of-world sales, global specialty products and active pharmaceutical ingredients. Segment definitions and reported geography can change, so investors should check the latest annual report.
Sun Pharma has products across chronic and acute therapies, with notable exposure to dermatology, ophthalmology, oncology, cardiology, diabetology, neurology, gastroenterology and other specialty or branded-generic categories. Product availability varies by country.
Sun Pharma earns revenue by developing, manufacturing, licensing and selling prescription medicines, specialty medicines, generic medicines and active pharmaceutical ingredients. Profitability depends on product mix, pricing, regulatory approvals, research spending, manufacturing efficiency and market competition.
No. India is a major market, but the company also has substantial international operations, including the United States, emerging markets and other global markets. Investors should monitor geographic sales mix and currency movements.
The NSE symbol is SUNPHARMA and the BSE security code is 524715. This page uses the Yahoo Finance-compatible NSE symbol SUNPHARMA.NS for chart and quote data.
Important factors include sales growth, specialty-product performance, US generic pricing, regulatory inspections, product approvals, litigation, research and development spending, acquisitions, currency changes, margins and overall market conditions.
Pharmaceutical companies face regulatory inspections, warning letters, product recalls, approval delays, pricing controls, patent disputes and quality-compliance requirements. Investors should review company disclosures and regulator updates for material developments.
Sun Pharma has paid dividends, but the amount and timing can change. Investors should verify the latest board recommendation, shareholder approval, record date and payment details from official exchange filings and company announcements.
Corporate-action history should be checked against official BSE, NSE and company filings because old records and adjusted prices can be interpreted differently. Do not rely only on third-party summaries.
Beginners can start with revenue growth, operating margin, net profit, cash generation, research and development spending, debt, return ratios and geographic sales mix. One quarter should be viewed in the context of multi-year trends and exceptional items.
Common listed comparisons include Dr. Reddy’s Laboratories, Cipla, Divi’s Laboratories and Lupin. Comparisons should account for differences in therapy mix, geography, specialty exposure, manufacturing model and valuation.
Monitor India sales growth, US sales, global specialty sales, gross and operating margins, R&D expense, regulatory updates, product launches, cash flow, acquisitions and management guidance.
No. Market feeds can be delayed or temporarily unavailable, and financial tables may not reflect the latest filing. Verify current prices, results, dividends, shareholding and corporate actions on official NSE, BSE and company investor-relations pages.
